Gilead Sciences, Inc. (NASDAQ: GILD) is listed among the 14 Best Pharma Dividend Stocks to Buy in 2025, appealing to income investors in the sector. The company gained recognition during the pandemic for its antiviral drug remdesivir, but has lagged behind the market due to growth concerns. GILD’s stable cash position and dividend payouts make it a strong pharma investment, with $1.8 billion in operating cash flow and $7.9 billion in cash and equivalents in Q1 2025. The company currently offers a quarterly dividend of $0.79 per share and has raised payouts annually since 2015, with a dividend yield of 2.90% as of July 17. While Gilead Sciences shows promise, some AI stocks may offer greater upside potential and less risk. For more insights, explore the best short-term AI stock in a free report.

Read more at Yahoo Finance: Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector